HealthQuad Secures Initial Rs 550 Crore in Commitments for Fund III

HealthQuad Secures Initial Rs 550 Crore in Commitments for Fund III



HealthQuad Fund III: A New Venture in Healthcare Investment




HealthQuad Fund III, backed by Quadria Group, has successfully completed its initial closing with commitments amounting to Rs 550 crore, representing over one-third of its target of Rs 1,700 crore. The backing came from current limited partners along with new contributors, which include local and international funds, institutions, and family offices. HealthQuad has already made its inaugural investment in Lifesigns, a platform leveraging AI for remote patient monitoring, and is currently assessing further investment prospects.

Overview of Fund III

Fund Management and Leadership

Fund III, succeeding HealthQuad Fund I and II, is managed by HealthQuad Advisors, a fully owned subsidiary of Quadria Group, led by Amit Varma, Abrar Mir, and Sunil Thakur. After parting ways with KOIS in 2025, Quadria Group retained a substantial portion of the team that managed the previous funds and has bolstered its leadership with the inclusion of Rahul Agarwal and Namit Chugh.

Investment Focus

Established in 2016, HealthQuad is dedicated to supporting entrepreneurs who are developing technology-focused healthcare solutions. Funds I and II have collectively invested in over 18 businesses, such as GoApptiv, Qure.ai, Redcliffe Labs, CureSkin, Strand Life Sciences, Medikabazaar, THB, Wysa, and ekincare.

Strategic Goals of Fund III

HealthQuad Fund III aims to concentrate on early-growth-stage ventures within the healthtech, medtech, biopharma technology, and healthcare delivery sectors. According to the insights provided by HealthQuad, these categories are projected to represent more than 40% of India’s potential $600 billion healthcare market by the year 2030. The firm intends to continue its support for healthcare startups that focus on enhancing access, affordability, and the quality of care through innovative technology, new business models, and product development.


Exit mobile version